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Abstract
The asynchronous secretion of gonadotrope LH and FSH under the control of GnRH is crucial for
ovarian cyclicity but the underlying mechanism is not fully resolved. Because prostaglandins (PG)
are autocrine regulators in many tissues, we determined whether they have this role in gonadotropes.
We first demonstrated that GnRH stimulates PG synthesis by induction of cyclooxygenase-2, via the
protein kinase C/c-Src/phosphatidylinositol 3′-kinase/MAPK pathway in the LβT2 gonadotrope cell
line. We then demonstrated that PGF2α and PGI2, but not PGE2 inhibited GnRH receptor expression
by inhibition of phosphoinositide turnover. PGF2α, but not PGI2 or PGE2, reduced GnRH-induction
of LHβ gene expression, but not the α-gonadotropin subunit or the FSHβ subunit genes. The
prostanoid receptors EP1, EP2, FP, and IP were expressed in rat gonadotropes. Incubations of rat
pituitaries with PGF2α, but not PGI2 or PGE2, inhibited GnRH-induced LH secretion, whereas the
cyclooxygenase inhibitor, indomethacin, stimulated GnRH-induced LH secretion. None of these
treatments had any effect on GnRH-induced FSH secretion. The findings have thus elaborated a
novel GnRH signaling pathway mediated by PGF2α-FP and PGI2-IP, which acts through an autocrine/
paracrine modality to limit autoregulation of the GnRH receptor and differentially inhibit LH and
FSH release. These findings provide a mechanism for asynchronous LH and FSH secretions and
suggest the use of combination therapies of GnRH and prostanoid analogs to treat infertility, diseases
with unbalanced LH and FSH secretion and in hormone-dependent diseases such as prostatic cancer.
GnRH IS THE central regulator of reproduction. GnRH alone, administered as hourly pulses,
is sufficient to restore fertility in men and women with hypothalamic hypogonadism. GnRH
binds and activates its cognate receptor in pituitary gonadotropes, resulting in the synthesis
and release of LH and FSH, which control ovulation and spermatogenesis (1-4). The
mechanisms mediating the differential synthesis and release of LH and FSH by GnRH during
the ovarian cycle and the termination of the ovulatory LH surge are not well understood.
Changes in GnRH pulse frequency have been implicated, but the ability to restore fertile
reproductive cycles of normal length on administration of unvarying hourly pulses of GnRH
to women with hypothalamic lesions (5-7) suggests that ovarian steroid hormones (estrogen
and progesterone) and peptide hormone (inhibin, activin, and follistatin) mediate the
differential LH and FSH responses to GnRH over the ovarian cycle (8).
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In vivo, cells are exposed to numerous stimuli, which simultaneously activate multiple
signaling pathways that potentially cross talk and affect the net biological outcome.
Gonadotropes are simultaneously exposed to pulses of hypothalamic GnRH, neurotransmitters,
melatonin, pituitary hormones, growth factors, and gonadal steroid and peptide hormones (9).
Signaling of GPCRs is mainly studied by introducing a single ligand to target cells and
analyzing the downstream events. To better mimic the in vivo situation, integrative signaling
may be addressed by simultaneous activation of the cell by a particular ligand, together with
effector molecules contributing to downstream pathway shared by GPCRs and growth factor
receptors. Eicosanoids represent such a model downstream effector system modulated by
multiple ligands. Eicosanoids are metabolites of arachidonic acid (AA) involved in the
regulation of reproduction, cancer, and the inflammatory, neuronal, cardiovascular,
gastrointestinal, respiratory, and immune systems (10,11). We have previously shown that
GnRH stimulates AA release from rat pituitary cells, followed by elevated expression of 12-
lipoxygenase and formation of 5-lipoxygenase products, which participate in GnRH actions
(3,12). Here we demonstrate a novel GnRH signaling pathway mediated by PGF2α and the FP
receptor and PGI2 and the IP receptor, which limit the homologous regulation of GnRH receptor
(GnRHR), whereas PGF2α also exerts selective inhibition of LH release. This mechanism may
underly the cyclical responsiveness of pituitary gonadotropes to GnRH and the asynchronous
LH and FSH release during the mammalian ovarian cycle.
RESULTS
GnRH Stimulates Cycooxygnease (COX)-2 Induction
Because COX-2 is the key enzyme in the eicosanoid synthesis pathway, we looked for
activation of COX-2 by GnRH. GnRH produced a marked time-dependent induction of COX-2
enzyme expression in the gonadotrope cell line LβT2 (13), as revealed by RT-PCR analysis
(Fig. 1A). Preincubation of the cells with the selective MEK inhibitor PD98059 abolished the
stimulatory effect of GnRH on COX-2 induction, indicating that activation of COX-2 by GnRH
is mediated by ERK. Further quantitative PCR (Q-PCR) revealed a marked induction of COX-2
by GnRH (40-fold; basal and GnRH-stimulated levels were 0.12 and 4.8, respectively, n = 3)
(Fig. 1B). This stimulatory effect was reduced by the selective inhibitors for MEK (PD98059),
JNK (JNKI), p38 (SB203580), phosphatidylinositol 3′-kinase (PI3K) (wortmannin), protein
kinase C (PKC) (GF109203X), and c-Src (PP2), with no significant effect on basal levels. The
data implicate the known GnRH-activated PKC/c-Src/MAPK pathway (14-17) in GnRH
induction of COX-2 (Fig. 1B). The substantial inhibition (50–75%) by all the inhibitors implies
that the various MAPK cascades do not converge on the same signaling molecules, but rather
act in parallel pathways to activate transcription factors, which act as a composite response
element during activation of COX-2 gene expression. The epidermal growth factor (EGF)
receptor kinase inhibitor, AG1478, had no significant effect on GnRH induced COX-2
expression. This accords with our observation that activation of MAPK by GnRH in
gonadotropes is not mediated by transactivation of the EGF receptor (18,19). The selective
inhibitors for iPLA2 [bromoenol lactone (BEL)] and for sPLA2 [thioetheramide-PC (TE-PC)],
but not that for cPLA2 (AACOCF3), reduced COX-2 induction by GnRH, suggesting that the
two PLA2 isoforms may also be involved in GnRH induction of COX-2. To examine the effect
of GnRH on COX-2 promoter activity, LβT2 cells were transiently transfected with the COX-2
promoter and treated with GnRH for various time periods (Fig. 1C). Activation was rapid and
reached maximal activation after 8 h of stimulation with GnRH (3-fold, P < 0.01), with a decline
to basal levels at 24 h. An increase in COX-2 mRNA stability by GnRH may explain the
discrepancy between the degree of mRNA induction (40-fold) and the degree and kinetics of
promoter activity (3-fold). It is also possible that the transfected promoter construct lacks the
full complement of regulatory elements. COX-2 protein expression was similarly regulated by
GnRH; maximal protein expression occurring at 8 h (2.5-fold; P < 0.05) (Fig. 1D). It is
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interesting to note that, whereas COX-2 protein levels have declined by 24 h of GnRH
stimulation, mRNA levels remained high. This suggests that there is an increased rate of protein
degradation and/or decreased translation.
GnRH Stimulates PGE2, PGI2, and PGF2α Production
To determine whether gonadotropes could elaborate prostanoids, we incubated the LβT2 cells
with GnRH for up to 24 h, with and without AA as substrate for the last 30 min of the incubation
period. Incubation with GnRH alone for up to 24 h had no effect on PG production but addition
of AA for the last 30 min of the incubation period resulted in a 2.5- to 3-fold increase (P <
0.05) in PGE2, PGI2, and PGF2α production (Fig. 2). Addition of AA alone had no effect on
PG production (data not shown). Addition of AA had previously been shown to be required to
demonstrate PG production (Ref. 20 and references therein).
Expression of Prostanoid Receptors in LβT2 Cells
After biosynthesis, prostanoids are transported out of the cell and act in an autocrine/paracrine
manner via cognate GPCRs (11). We therefore examined prostanoid receptor expression in the
immortalized gonadotrope LβT2 cell line (13), which serve as a gonadotrope cell model to
dissect the signaling of the GnRHR. Specific staining for EP1, EP2, EP3, EP4, FP, and IP was
observed in LβT2 cells (Fig. 3A). Specificity was demonstrated by preabsorption of the
antibodies with the specific peptides used for the immunization (C). The expression of EP1,
EP2, EP3, EP4, FP, and IP in LβT2 cells was further demonstrated by RT-PCR (Fig. 3B).
Cross Talk between Prostanoid and GnRHRs
The known marked homologous induction of the GnRHR promoter construct by GnRH itself
(21) was significantly reduced by PGF2α and the stable analog of PGI2, iloprost, but not by
PGE2 (Fig. 4A). Furthermore, cotreatment of LβT2 cells with GnRH and PGF2α or iloprost for
6 h reduced GnRH binding [2180 ± 437 counts per minute (cpm) and 2587 ± 454 cpm
respectively; SEM, n = 3, P < 0.01] when compared with binding in cells incubated with GnRH
alone (6134 ± 737 cpm; SEM, n = 3), or with GnRH and PGE2 (6254 ± 1022 cpm; SEM, n = 3). To
elucidate the mechanisms involved in the inhibitory action of the PGs we first investigated
whether they compete with the binding of GnRH for its cognate receptor. As shown in Fig.
4B, GnRH binding to LβT2 cells was not affected by the presence of PGE2, PGF2α or iloprost
(each at 500 nM). We therefore proceeded to examine initial signaling events after receptor
binding. The mechanism of GnRH stimulation of the GnRHR promoter is known to be via
activation of its predominant signaling pathway (Gαq and PLC-β) (21). We confirmed this by
demonstrating that GnRH stimulation of the GnRHR promoter was progressively inhibited by
increasing concentrations of the PLC-β inhibitor (U73122) (Fig. 4C) and that this correlated
well with the concomitant decrease in InsP production (Fig. 4D). Thus, it was feasible that the
inhibitory effects of PGF2α and iloprost on the GnRHR promoter were mediated via an
inhibition of InsP production. This notion is supported by our demonstration that PGF2α and
iloprost inhibited GnRH stimulation of InsP formation but had no significant effect on basal
levels, whereas PGE2 was ineffective (Fig. 4E).
Effects of Prostanoids on GnRH-Stimulated α-Gonadotropin Subunit (αGSU), LHβ, and
FSHβ Gene Expression
To determine whether prostanoids affect the GnRH transcriptional regulation of gonadotropin
subunit genes (αGSU, LHβ, and FSHβ). LβT2 cells were transfected with αGSU, LHβ, or
FSHβ promoters driving a luciferase reporter (Fig. 5). The exogenous addition of the PGs had
no significant effect on GnRH induction of αGSU (Fig. 5A) and FSHβ (Fig. 5C) genes.
However, PGF2α but not PGE2 or iloprost, reduced GnRH activation of the LHβ promoter (Fig.
5B; P < 0.05).
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Expression of Prostanoid Receptors in Rat Gonadotropes
We examined the expression of the various prostanoid receptors in rat pituitaries by
immunohistochemistry and immunofluorescent microscopy using confocal microscopy (Fig.
6). Specific expression of a given receptor was followed by colocalization with pituitary
hormones for potential cell-specific expression. Specific staining for receptors for PGE2 (EP1,
EP2, EP3, and EP4), for PGF2α (FP) and PGI2 (IP) were demonstrated by
immunohistochemistry. Negative controls included omission of the first antibody, pretreatment
with preimmune serum and peptide immunogen competition. EP1 and EP2 staining colocalized
to LH-containing gonadotropes, which comprise about 10–15% of the total cell population in
the adult rat pituitary (22) (Fig. 6). EP3 and EP4 colocalized to prolactin-containing cells
(mammotropes) and the GH-containing cells (somatotropes), respectively, which comprise
about 20–30% and 40% of the total cell population in the adult rat pituitary (22) (data not
shown). The PGI2 receptor IP and the PGF2α receptor FP were found to colocalize to the
gonadotropes (Fig. 6).
Differential Inhibitory Effects of PGF2α on LH Release
Because prostanoids affect gonadal function (23) and GnRH secretion (24), it is not feasible
to study their direct effects on pituitary function in vivo. We therefore sought to obtain direct
evidence for a role for PGs on GnRH stimulation of gonadotropin secretion using an ex vivo
approach. Rat pituitaries were stimulated with GnRH alone or in combination with
indomethacin (COX enzyme inhibitor) or PGs. Indomethacin and the PGs had no significant
effect on basal gonadotropin secretion (Fig. 7). COX enzyme inhibition by indomethacin
treatment enhanced the GnRH-stimulated LH but not FSH secretion (Fig. 7, A and B; P <
0.05). Co-stimulation of pituitaries with GnRH and PGE2 or iloprost had no effect on the
secretion of either gonadotropin in response to GnRH. However, PGF2α inhibited the GnRH-
stimulated LH release, but had no effect on FSH release (Fig. 7, C and D; P < 0.01).
DISCUSSION
GnRH is the central regulator of the reproductive system through the differential and
asynchronous stimulation of LH and FSH (3,4,21,25). The precise cyclical regulation of LH
and FSH is crucial to normal reproduction and dysregulation results in conditions such as
polycystic ovarian syndrome and amenorrhea anorexic patients (26). Feedback by ovarian
steroid and peptide hormone at the pituitary gonadotrope and changes in GnRH pulse frequency
and GnRHR expression have been proposed to contribute to this cyclical secretion (27,28).
GnRH auto-sensitizes the gonadotropes by up-regulating its own receptor preparatory to the
onset of puberty and for the LH surge that triggers ovulation (1,2,29). GnRHR number increases
from the evening of diestrus in rodents until late afternoon of proestrus, which culminates in
the surge in LH secretion in late proestrus (2,29). Conversely, potential signals to down-
regulate GnRHR in mouse gonadotropes include the gonadal steroids and changes in pulse
frequencies of GnRH (21,30). In the sheep, the gonadotrope becomes refractory to GnRH after
the LH surge (31). Despite these advances, the mechanisms involved have not been fully
elucidated. We have now demonstrated that GnRH stimulates PG biosynthesis, which inhibits
GnRHR and LH, but not FSH gene expression and hormone secretion. These findings thus
provide a potential autocrine mechanism of refractoriness to GnRH after the LH surge and
asynchronous gonadotropin secretion during the ovarian cycle (Fig. 8). Our results further
provide a molecular mechanism to modulate GnRHR number and to mediate gonadotrope
desensitization during prolonged GnRH stimulation. This is of particular importance because
it provides a mechanism for the down-regulation of the GnRHR that is the only mammalian
GPCR that lacks a cytoplasmic carboxyl-terminal tail and consequently does not undergo rapid
desensitization and internalization as in other GPCRs (32-35). The loss of the carboxyl-
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terminal tail and lack of rapid desensitization is thought to have evolved to allow the prolonged
LH surge, which is required for ovulation in women (32).
Multiple ligands interact with pituitary gonadotropes. In addition to GnRH, gonadal steroids
and peptide hormones, growth factors, neurotransmitters, melatonin, and pituitary hormones
have all been demonstrated to act as regulators (9). Hence, addition of a single ligand to cultured
cells in vitro does not mimic the in vivo situation. Recognizing these caveats, attempts have
been made to study the effect of multiple ligands simultaneously. Here we took another
approach, which is based on the assumption that because many ligands stimulate PGs
production, one can use these signaling molecules to elucidate the integrative signaling for a
given ligand and better mimic the in vivo situation. Moreover, prostanoids may play a role in
mediating the effects of ligands other than GnRH.
Eicosanoids are hydrolyzed from AA by PLA2, a super family of enzymes consisting of at least
14 groups (I–XIV) and at least 19 members (36,37). Once released by PLA2, AA is converted
to prostanoids (PG and thromboxanes) via COX-1, COX-2, and prostanoid synthases or
undergoes dioxygenation to hydroperoxide derivatives by lipoxygenases or to epoxygenase
products via cytochrome p450 epoxygenase (cyp2C11) (Ibid). We have previously shown that
GnRH stimulates AA release from rat pituitaries (38) and have implicated 5-lipoxygenase and
12-lipoxygenase products of AA in GnRH actions (3,12). Here, we have investigated the cross
talk of GnRH and prostanoid receptors.
Because the inducible COX isoform (COX-2) is the key enzyme in the prostanoid synthesis
pathway, we looked for activation of COX-2 by GnRH and showed a 40-fold increase in
expression. A recent report documented that induction of COX-2 by angiotensin II reflects an
immediate-early gene response (39). Our results support the findings because we show a rapid
activation of the COX-2 promoter by GnRH (2 h), mRNA and protein production (4–8 h). The
use of pharmacological inhibitors revealed a role for the PKC/c-Src/MAPK pathway, but not
for EGF receptor kinase in the GnRH induction of COX-2. The results accord with previous
studies suggesting that activation of MAPK by GnRH in gonadotropes is mediated mainly by
PKC and c-Src but not via transactivation of the EGF receptor (14,15,18,19,40-46). MAPKs
have previously been implicated in the induction of COX-2 (47,48) and a role for PI3K and c-
Src in COX-2 expression has been demonstrated (49). Indeed, GnRH activates c-Src and PI3K
in LβT2 cells (19,50). We also examined the role of PLA2 that has been implicated in COX-2
induction (51). Using specific inhibitors (36,37), we found that iPLA2 and to a lesser degree
sPLA2, but not cPLA2 as in Ref. 51, participate in GnRH induction of COX-2. Hence,
iPLA2 and sPLA2 may also be involved in the induction of COX-2 possibly by a feed-forward
mechanism via the newly formed PGs as described below. Thus, the signaling pathways and
the various PLA2 and MAPK members are likely to be implicated in COX-2 induction in an
agonist and cell context-dependent manner (39,47,48,51) (present results). Activated ERK
phosphorylates various transcription factors (e.g. c-Jun, c-Fos, ELK-1, and Sap-1) resulting in
the activation of activator protein (AP)-1 (52), which binds and activates the COX-2 promoter
via the CRE/ATF response element (53). ERK phosphorylation is also required for persistent
activation of nuclear factor-κB, which is also involved in COX-2 transcription (54).
AA is converted to prostanoids via activated COX-2 and specific PG synthases (11). We
therefore investigated whether GnRH activation of COX-2 results in PG synthesis. We first
failed to detect production of PG after prolonged incubation of the cells with GnRH. We
reasoned that although PLA2 activation by GnRH may be rapid (min), COX-2 induction is a
slow process (4–8 h) and might be a limiting step in PG production. Furthermore, due to rapid
uptake, the availability of free AA is a rate-limiting step in PG synthesis. Therefore, the two
events, namely induction of COX-2 and availability of free AA, may not be appropriately and
temporally coordinated during prolonged incubation periods in vitro. Indeed, exogenous AA
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was needed to demonstrate PGE2 production by IL-1 (20). Similarly, we could only detect
stimulation of PG production by GnRH when exogenous AA was added for the last 30–60 min
of the incubation period. The dose of AA used here (1 μM), is below the Michaelis-Menten
constant (Km) values of 5-lipoxygenase and COX (55). In vivo, pituitary gonadotropes are
exposed to GnRH pulses every 30–90 min (according to the species) thus, COX-2 induced in
previous pulses may act on AA generated by PLA2 in the current pulse resulting in rapid
formation of PGs. Once formed, PGF2α and PGI2 are now capable of inhibiting GnRH-
stimulated phosphoinositide turnover (30 min), GnRHR promoter activity (4 h), GnRH binding
sites and LHβ promoter activity (6 h) and LH release (8 h). Provided COX-2 was activated by
GnRH for 2–4 h, once AA was added for 30 min (at any preincubation with GnRH for up to
24 h), we could detect the formation of the PGs at the end of the 30 min exposure to AA (Fig.
2). These temporal differences in activation of enzymes and substrate generation for PG
production, which in turn regulate GnRHR and gonadotropin provides an elegant mechanism
for translating changes in GnRH pulse frequency into physiological outputs.
Prostanoids are known to act in an autocrine/paracrine manner via cognate GPCRs (11). We
therefore examined the expression of the various prostanoid receptors in rat pituitaries. Specific
expression of receptors for PGE2 (EP1, EP2, EP3, and EP4), for PGF2α (FP) and PGI2 (IP)
were found. EP1, EP2, IP, and FP colocalize to rat gonadotropes (Fig. 6), which comprise about
10–15% of the total cell population in the adult rat pituitary (22). EP3 and EP4 are present in
the prolactin and GH producing cells, the mammotropes (20–30% of the total cell population)
and somatotropes (∼40% of the cells), respectively (data not shown). The prostanoid receptors
EP1, EP2, EP3, EP4, IP, and FP were detected in the embryonic-derived mouse LβT2
gonadotrope cells. The staining of the various prostanoid receptors was observed in the
cytoplasmic and perinuclear membrane regions, and in some cases in the nucleus (Fig. 3).
Because prostanoid receptor signaling is rapidly terminated, it is likely that only a small fraction
of the receptor pool is at the plasma membrane under basal conditions and prostanoid receptors
may rapidly cycle between the cell surface and the intracellular pool, with a relatively short
half-life at the plasma membrane, as for many GPCRs. The predominantly intracellular staining
observed here was also reported by others for different cell models. EP1 has been described to
reside in the cytoplasm (56). The thromboxane A2/prostaglandin H2 receptor was found in the
endoplasmic reticulum (57) and EP3 and EP4 were found in the nuclear envelope (58,59). It
is interesting to note that the dogma that PLA2 liberates AA from the sn-2 position of plasma
membrane phospholipids has been challenged by the observations that both cPLA2α and
COX-1/2 reside in the endoplasmic reticulum and the nuclear envelope membrane, where PGs
are formed (60). It is therefore tempting to suggest that, aside from PG secretion and binding
to receptors on the plasma membrane, PGs may also act intracellularly in the vicinity of their
site of origin. The finding that EP3 and EP4 are present in LβT2 cells but not in rat pituitary
gonadotropes may reflect incomplete differentiation of this gonadotrope-derived cell line and
that maturation of murine gonadotropes may involve the loss of expression of both EP3 and
EP4.
These studies begged the question as to whether the newly formed PGs affect the kernal
physiological outcome of GnRH actions, namely the transcriptional regulation of gonadotropin
subunits (αGSU, LHβ, and FSHβ) and gonadotropin secretion (21). Treatment with PGs had
no significant effect on the induction of αGSU and FSHβ genes by GnRH. However, PGF2α,
but not PGE2 or PGI2, significantly reduced the activation of the LHβ promoter by GnRH. We
also investigated whether the exogenous addition of PGs affected the homologous induction
of the GnRHR (21). The induction of GnRHR by GnRH was markedly reduced by PGF2α and
PGI2, but not by PGE2. Homologous activation of the mouse GnRHR identified a role for PKC/
MAPK/AP-1 signaling and CRE elements (21). Phosphoinositide turnover is tightly coupled
to the PKC/MAPK/AP-1/CREB pathways (14,52,61). We therefore targeted phosphoinositide
turnover as the first potential upstream signaling module for PG action. We found inhibition
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of GnRH-stimulated InsP formation by PGF2α and PGI2, but not PGE2, in line with their
inhibition of the GnRHR. The link of phosphoinositide turnover to GnRHR induction was
revealed by the use of the PLC-β inhibitor U73122, which produced a dose-related inhibition
of GnRH-induced InsP formation and GnRHR promoter activity. Thus, inhibition of GnRHR
by PGF2α and PGI2 appears to be mediated by an inhibition of phosphoinositide turnover,
perhaps leading to an alteration of protein complexes at the AP-1 sites in the promoter (21).
Our findings present an enigma in that these ligands bind the FP and IP receptors, which
stimulate InsP (11). Thus, in gonadotropes expressing GnRH, FP, and IP receptors (which are
all believed to stimulate lnsP), EP1 and EP2 (which are believed to stimulate lnsP and cAMP,
respectively), a more complex picture emerges and activation of the FP and IP receptors
actually inhibits GnRHR stimulation of InsP. Hence, the presence of multiple receptors in the
same cell may result in a different signaling profile from that obtained by over expressing a
single prostanoid receptor. The dogma that PG receptors have discrete signaling pathways
(11) should therefore be revisited because our results suggest that cell context and expression
of multiple prostanoid receptors in the same cell can dictate the flavor of the signaling. The
mechanism involved in PG inhibition of GnRH-stimulated InsP formation may include
potentiating GnRH-stimulated PKC isoforms activation (62), which can feed back and inhibit
PLC-β, or activation of specific InsP phosphatases.
Our demonstration of EP1, EP2, FP, and IP receptor expression in rat gonadotropes by double
fluorescent confocal microscopy suggested that PGE2, PGF2α, and PGI2 might have direct
effects on gonadotrope function. In vivo support for our in vitro cell line findings on inhibitory
effects of endogenous PG on GnRHRs and LHβ expression was obtained by using an ex vivo
approach of rat pituitaries incubated with GnRH alone or in the presence of the COX inhibitor,
indomethacin or various PGs. Inhibition of COX enzyme activity by indomethacin treatment
enhanced GnRH-stimulated LH but not FSH secretion. Furthermore, PGF2α, but not PGE2 or
PGI2, inhibited GnRH-stimulated LH, but had no effect on FSH release. Thus, only the FP
receptor in gonadotropes appears to regulate LH in this nondynamic system. Whereas the FP
receptor therefore appears to play a significant role in differential gonadotropin secretion in
response to GnRH, the findings do not rule out more subtle roles for the IP and EP receptors
expressed in gonadotropes.
The data suggest that the reduction of GnRHR expression is insufficient to reduce LH secretion
as evident from the lack of effect of PGI2, which like PGF2α reduced GnRHR expression but
had no effect on LH secretion. Hence, the reduction of both GnRHR and LHβ expression, as
observed with PGF2α are required to affect the LH exocytotic apparatus. The data also suggest
that FSH secretion is less sensitive to the reduction of GnRHRs because it was not affected by
PGI2 and PGF2α. The results are in line with a report that found that at high GnRHR
concentrations, GnRH activates the αGSU and LHβ genes and exerts a selective inhibition of
the FSHβ gene, whereas the FSHβ gene is optimally activated at lower number of GnRHRs
(27).
In summary, our results provide a novel inside-out molecular mechanism to regulate GnRHR
number and to mediate the differential LH and FSH secretion during GnRH stimulation (Fig.
8). These findings provide a basis for the use of combination therapies of GnRH and prostanoid
analogs to treat infertility and diseases with unbalanced LH and FSH secretion such as
polycystic ovarian syndrome. Combination therapy may also be contemplated in hormone-
dependent disease such as prostatic cancer and endometriosis. These diseases are currently
treated with GnRH analogs for inhibition of gonadotropin and hence sex steroids. Because PGs
affect GnRHR and LHβ, modulation of PG input on gonadotropes has the potential to increase
the efficacy of the GnRH analogs.
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MATERIALS AND METHODS
Materials
Culture medium was from Invitrogen Inc. (Paisley, Scotland, UK). Penicillin-streptomycin
and fetal calf serum (FCS) were from PAA Laboratories Ltd. (Middlesex, UK). GnRH was
from Peninsula (St. Helens, UK). Prostaglandin E2 (PGE2), the stable PGI2 analog Iloprost,
prostaglandin F2α (PGF2α), rabbit polyclonal antibodies to the various PG receptors and
respective peptides, arachidonyl trifluoromethyl ketone (AACOCF3), TEPC, BEL, and ELISA
kits for the PG were from Cayman Chemical Co. (Alexis Corp., Nottingham, UK). Rabbit
antirat antibodies for LHβ and prolactin and guinea pig antirat GH were from National
Hormone and Peptide Program [National Institutes of Health (NIH)]. Secondary horseradish
peroxidase (HRP)-conjugated goat antimouse antibodies or goat antirabbit antibodies were
from Jackson ImmunoResearch Laboratories (West Grove, PA). PD980595, a peptide JNK
inhibitor (JNKI; Calbiochem 420116), SB203580, GF109203X, wortmannin, PP2, AG1478,
and U73122 were from Calbiochem (Nottingham, UK).
Cell Culture
LβT2 cells were kindly obtained from P. Mellon (University of California, San Diego, San
Diego, CA). The cells were cultured in matrigel (Becton Dickinson, Oxford, UK)-coated plastic
flasks in DMEM/10% FCS/glutamine medium (Sigma, Poole, UK), with 1% antibiotics (stock
500 IU/ml penicillin and 500 μg/ml streptomycin) at 37 C and 5% CO2 (vol/vol) (19).
Immunohistochemistry
Adult rat pituitaries were fixed for either 6 or 24 h in Bouins, 4% neutral buffered formaldehyde
(NBF) or modified Davidson's fixative. Pituitaries were processed to paraffin using standard
procedures and 5μm sections were mounted on superfrost plus slides (BDH, Poole, Dorset,
UK). Cells were cultured on chamber slides (Lab Tek, Naperville, IL) rinsed for 5 min in PBS
followed by 10 min fixation. Each antiserum was tested using a range of dilutions on paraffin
sections of rat pituitary fixed as above. They were evaluated with and without heat induced
antigen retrieval using a pressure cooker (Tefal, Cambridge, UK) and 0.01 M citrate. For all
antisera tested, antigen retrieval was not required. Negative controls were either omission of
primary antisera or peptide absorption of antisera using a 10-fold excess of peptide incubated
at 4 C overnight. Antisera were evaluated on LβT2 cells after 10 min fixation in 4% NBF.
Sections were dewaxed in xylene before being rehydrated in graded ethanol. Sections were
blocked in 3% hydrogen peroxide in Methanol for 30 min (HRP and Tyramide detections only),
rinsed in running tap water then washed for 5 min in Tris-buffered saline (TBS, 0.05 M Tris;
and 0.85% NaCl, pH 7.4). Sections were blocked in 20% normal swine serum in TBS (TBS/
NSS) for 30 min at room temperature. Slide were drained and incubated with Primary antiserum
diluted in TBS/NSS overnight at 4 C. After two 5-min washes in TBS, sections were incubated
for 30 min with Swine anti Rabbit Biotinylated at 1:500 dilution in TBS/NSS for 30 min at
room temperature. After two 5-min washes in TBS, sections were incubated for 30 min with
HRP-conjugated avidin-biotin complex (ABC-HRP) (Dako, Cambridgeshire, UK). Sections
were washed for a further two 5-min washes in TBS before visualizing with diaminobenzidine
(Dako).
Immunofluorescence (LH, Prolactin, and GH)
After dewaxing and methanol/hydrogen peroxide blocking (if necessary) as described above.
Sections were incubated in 20% normal goat serum in PBS (NGS/PBS). Slides were drained
and incubated with Primary antiserum diluted in NGS/PBS overnight at 4 C. After two 5-min
washes in PBS, sections were incubated for 30 min with either Goat antiguinea pig biotinylated
at 1:500 dilution in PBS/NGS for 30 min at room temperature (prolactin, GH), or goat
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antimouse Alexa 488 at 1:200 dilution in PBS/NGS (LH). For GH or prolactin staining, after
two 5-min washes in PBS, sections were incubated for 30 min with Streptavidin Alexa 488.
All sections were washed for a further two 5-min washes in PBS before being counterstained
in TOPRO-3 at 1:2000 dilution and coverslipped using permaflour (Coulter, Buckinghamshire,
UK).
Fluorescent Tyramide Detection
After dewaxing and methanol/hydrogen peroxide blocking as described above. Sections were
incubated in 20% NGS/PBS. Slides were drained and incubated with primary antiserum diluted
in NGS/PBS overnight at 4 C. After two 5-min washes in PBS, sections were incubated for 30
min with goat antirabbit peroxidase at a 1:200 dilution in PBS/NGS for 30 min at room
temperature. After two 5-min washes in PBS, sections were incubated for 10 min with
Tyramide Cy3 Sections were washed for a further two 5-min washes in PBS before being
counterstained in TOPRO-3 at 1:2000, and cover slipped using permafluour (Coulter).
Immunofluorescent Colocalization
After standard immunofluorescent detection as described above (prolactin, GH, and LH)
sections were blocked in peroxide block for 10 min (Dako) before detection of EP1–4, IP, or
FP using Fluorescent Tyramide Detection as described above. After two 5-min washes in PBS
sections were counterstained in TOPRO-3 at 1:2000 and cover slipped using permaflour.
Bright-field images were captured using an Olympus (Center Valley, PA) Provis microscope
fitted with a Kodak (Rochester, NY) DCS 330 digital camera Fluorescent images were captured
using a Zeiss (Oberkochen, Germany) LSM 510 confocal microscope.
PCR
Total RNA was isolated from cells using Tri-reagent (Sigma) according to the manufacturer's
instructions. The RNA yield was calculated using ultraviolet spectrophotometry and samples
were stored as an ethanol precipitate at −80 C before RT-PCR analysis. RNA samples (5 μg)
were reverse-transcribed using deoxynucleotide triphosphate (dNTPs) (0.2 mM each), random
primers (200 ng), ribonuclease inhibitor (2 U/μl) and SuperScript reverse transcriptase (10 U/
μl; Invitrogen). The reverse transcription product (200 ng cDNA) was then amplified by PCR
using homologous primers designed from the mRNA sequences of the various EP receptors
and the COX enzymes. The sequence of the primers (forward and reverse primers respectively)
was as follows: EP1, 5′-CGCTCCTTGCGGCATTAGTGTGC, 5′-
CCAACACCACCAACACCAGCAGG; EP2, 5′-TAGGGCAGGTGAGGCACAGAAGC, 5′-
GAAAGGAGCCACTGACGACTCTTGC; EP3, 5′-ATGTGTGTGCTGTCCGTCTGTTGG,
5′-CAACCAGACTCTCAGATTATCC; EP4, 5′-
AGACACCACCTCGCTGAGAACTTTGC, 5′-CTTCAAGCCTGGGCACTCAAGGACC;
FP, 5′-TAGGGAGGAAAGAGAGGTGGAACC, 5′-TGACTTCTGTCTAAATCTCTGG; IP,
5′-GATGCCGAAGGTTCTATGGC, 5′-TGTGTCCAGCAATGTCACCTGC; COX-2, 5′-
TGCCACCTCTGCGATGCTCTTCC, 5′-CAGACTCCCTTGAAGTGGGTCAGG. Primers
were selected to match sequences located in separate exons, enabling detection of spliced
transcripts. The PCR mix consisted of 1× reaction buffer containing 1.5 mM MgCl2, 0.2 mM
dNTPs, 0.2 μM of each primer and 1.25 U Taq DNA polymerase (Abgene, Epsom, Surrey, UK).
Samples were denatured at 94 C for 5min, and then amplified by 35–40 cycles of 94 C for 1
min, 60 C for 30 sec and 72 C for 40 sec with a final extension of 72 C for 10 min. After
amplification, 10 μl of each sample was visualized on a 1% agarose gel. Normal mouse uterus
was used as a positive control (63).
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Taqman Quantitative RT-PCR
RNA samples were quantified and reverse-transcribed using 5.5 mM MgCl2, 0.5 mM of each
dNTP, 2.5 μM random hexamers, ribonuclease inhibitor (0.4 U/μl) and 1.25 U/μl Multiscribe
reverse transcriptase (all from Applied Biosystems, Warrington, Cheshire, UK). RNA (200
ng) was added to each 10 μl reverse transcription reaction and samples were incubated for 60
min at 25 C, 45min at 48 C and 5 min at 95 C. The reaction mix for the PCR consisted of 1×
mastermix, ribosomal 18S forward and reverse primers, ribosomal 18S probe (50 nM; all from
Applied Biosystems), forward and reverse primers for COX-2 (300 nM) and COX-2 probe (200
nM) (all from Biosource UK, Nivelles, Belgium). The reaction mix (48 μl) was aliquoted into
tubes and 2 μl cDNA was added. Duplicate 24-μl samples plus positive and negative controls
were placed in a PCR plate and wells were sealed with optical caps. The PCRs were carried
out using an ABI Prism 7700 (Applied Biosystems). All primers and probes were designed
using the PRIMER express program (Applied Biosystems). The sequences of the COX-2
primers (forward, reverse, and probe, 6-carboxy fluoroscein labeled) were: COX-2, 5′-
GCTTCGGGAGCACAACAGA-3′; 5′-TGGTTTGGAATAGTTGCTCATCAC-3′; 5′-
TGTGCGACATACTCAAGCAGGAGCATC-3′. Data were analyzed and processed using
Sequence Detector version 1.6.3 (Applied Biosystems) according to the manufacturer's
instructions. Results were expressed relative to an internal positive standard cDNA obtained
from a single sample of mouse uterus (63).
PG Production
LβT2 cells were grown in 4 × 12-well plates (5 × 105 cells/well). Cells were incubated in serum-
free DMEM, 0.2% FCS overnight at 37 C. The cells were washed with DMEM and incubated
with or without GnRH for various time periods as detailed in the legends. Some of the wells
received exogenous AA (1 μM) for the last 30 or 60 min of each incubation time. At the end of
the incubation time, the media were removed and stored at −20 C for determination of PGE2,
PGI2, and PGF2α by ELISA as described in Ref. 64.
Reporter Gene Assays
The reporter constructs are described in (65), except 2307/+49 human COX-2 promoter
[pGL3.C2.2 (P6P5)], which was obtained from R. Newton (University of Warwick, Coventry,
UK). Reporter gene assays were carried out as recently described (19,65,66).
Receptor Binding Assays
Whole cell receptor binding assays used the 125I-[His (5), D-Tyr (6)]GnRH analog as described
(67).
Inositol Phosphates Assays
LβT2 cells were incubated with GnRH (100 nM) in the presence and absence of PGE2, iloprost
or PGF2α (500 nM) for 30 min and total inositol phosphate production was determined as
previously described (68).
Gonadotropin Secretion
Pituitaries from 23-d-old Wistar-derived female rats were preincubated with indomethacin (8
μM), PGE2, iloprost or PGF2α (500 nM) in Krebs-Ringer-bicarbonate for 4 h, washed twice and
further incubated with the drugs with or without GnRH (100 nM) for 3 h (Indomethacin + GnRH)
and 4 h (PG + GnRH). The medium was collected and LH and FSH were determined by RIA
using the kit provided by the National Hormone and Peptide Program (NIH).
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Data Analysis
Results from two or three experiments were expressed as mean ± SEM. Where appropriate, data
were subjected to statistical analysis withy one-way ANOVA and Fisher's protected least
significant difference tests (Statview 5.0; Abacus Concepts Inc., Carpinteria, CA), and
statistical significance accepted when P < 0.05.
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Fig 1. GnRH Induction of COX-2 Activity
A, Effect of GnRH on COX-2 induction as revealed by RT-PCR. Subconfluent LβT2 cells
were incubated and some groups were pretreated with the selective MEK inhibitor PD98059
(50 μM for 20 min) before the addition of GnRH (10 nM) for the time indicted. COX-2 was then
determined by qualitative RT-PCR. Negative (H2O) and positive (U, uterus) controls are also
shown. B, Quantitative-PCR for COX-2 induction by GnRH. Subconfluent LβT2 cells were
pretreated for 20 min with the following selective inhibitors: for MEK (PD98059, 50 μM), for
JNK (JNK inhibitory peptide, 2 μM), for p38 (SB203580, 10 μM), for PI3K (Wortmannin, 25
nM), for PKC (GF109203X, 3 μM), for c-Src (PP2, 5 μM), for iPLA2 (BEL, 20 μM), for sPLA2
(TE-PC, 25 μM), for cPLA2 (AACOCF3, 25 μM) and for EGF receptor kinase (AG1478, 5 μM).
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Cells were then stimulated with GnRH (100 nM for 8 h) and COX-2 was determined by Q-PCR.
C, Effect of GnRH on COX-2 promoter activity. Subconfluent LβT2 cells were seeded into
six-well plates and incubated overnight at 37 C before transfecting with 0.3 μg of −2307/+49
human COX-2 promoter. Renilla (33 ng) expression vector was also included as a measure of
transfection efficiency and as an internal control. The transfected cells were serum starved for
18 h. GnRH (100 nM) was added for the indicated time points and cells were then harvested
and assayed using a Dual-light Luciferase assay kit (Promega) in a FLUOStar Optima
luminometer. Luciferase activity was normalized for Renilla to correct for transfection
efficiency. Results for promoter activity are expressed as fold increase relative to untreated
controls (n = 6). D, Effect of GnRH on COX-2 protein expression. LβT2 cells were grown in
4 × 12-well plates (5 × 105 cells/well). Cells were incubated in serum-free DMEM, 0.2% FCS
overnight at 37 C. The cells were washed with DMEM and incubated with or without GnRH
(100 nM) for various time periods and COX-2 was detected by Western blotting. The blot was
re-run with antitotal ERK antibody to correct for equal loading of the samples. A representative
gel is shown, and bars are the mean from triplicate samples (ANOVA: *, P < 0.05, **, P <
0.01 compared with control).
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Fig 2. GnRH Stimulates PG Production
LβT2 cells were serum starved overnight washed with DMEM and incubated with GnRH (100
nM). Some of the wells received exogenous AA (1 μM) as substrate for the last 30 min of each
incubation time. A, PGE2; B, PGF2α; and C, PGI2 levels were determined by ELISA. Addition
of AA alone had no effect on PG production. One-way ANOVA established that *, P < 0.05
and ***, P < 0.001.
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Fig 3. Prostanoids Receptor Expression in LβT2 Cells
A, LβT2 cells were fixed for 10 min in 4% NBF and immunostained with antibodies to EP1,
EP2, EP3, EP4, IP, and FP at a 1:200 dilution. To ensure specificity, the primary antibodies
were also incubated with the immunization peptides at a 10-fold excess overnight at 4 C
(control, C). After washes in TBS, sections were incubated for 30 min with ABC-HRP, and
washed in TBS before visualization with diaminobenzidine (bar,50 μm). B, Qualitative RT-
PCR of prostanoids receptors in LβT2 cells. Total RNA isolated from subconfluent LβT2 cells
was reversely transcribed and aliquots of single-stranded cDNA were subjected to PCR (with
negative controls, N) using appropriate oligonucleotide primers provided in Materials and
Methods. PCR products were analyzed by UV fluorescence of ethidium bromide-stained DNA
after agarose gel electrophoresis alongside DNA size markers. RNA isolated from rat uterus
(U) served as a positive control.
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Fig 4. Effect of PG on GnRHR Regulation
A, Effect of PG on GnRH-induced GnRHR promoter activity. LβT2 cells were transiently
transfected with control pGL3 or GnRHR-Luc, pretreated for 30 min with PGE2, iloprost or
PGF2α (500 nM) followed by addition of GnRH (100 nM) and continuous PG treatment for 4 h.
Luciferase activity was measured, corrected for transfection efficiency and expressed as
relative light units (RLU×103). Basal levels of pGL3 and GnRHR-Luc were not detectable
(ND) after PG treatment, but there was no effect of PG treatment on the cotransfected control
CMV-β-galactosidase plasmid. Fold stimulation was calculated relative to GnRH treated and
a representative experiment of the three performed, each done in triplicate is shown. B, Effect
of PG on GnRH binding. LβT2 cells were pretreated for 30 min with PGE2, iloprost or
PGF2α (500 nM) followed by a competitive binding assay for GnRH in the presence and absence
of PGE2, PGF2α or iloprost (500 nM) as detailed in Materials and Methods. A representative
experiment of the three performed is shown. C and D, Effect of the phospholipase C inhibitor,
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U73122 on GnRH-induced GnRHR promoter activity and phosphoinositide turnover. C,
LβT2 cells were transiently transfected with GnRHR-Luc, pretreated with U73122 for 30 min,
followed by a further addition of GnRH (100 nM for 4 h). Luciferase activity was measured,
corrected for transfection efficiency and expressed as relative light units (RLU×103). D, LβT2
cells were pretreated with U73122 for 30 min, followed by stimulation with GnRH (100 nM for
30 min) and total inositol phosphate (InsP) production was determined. A representative
experiment of the three preformed, each done in triplicate is shown. E, Effect of PG on GnRH-
induced phosphoinositide turnover. LβT2 cells were pretreated for 30 min with PGE2, iloprost
or PGF2α (500 nM) followed by a 30-min incubation with increasing doses of GnRH in the
presence and absence of PGE2, PGF2α or iloprost (500 nM), and total inositol phosphates (InsP)
production was determined as detailed in Materials and Methods. A representative experiment
of the three preformed, each done in triplicate is shown. One-way ANOVA determined that
***, P < 0.001; **, P < 0.01; and *, P < 0.05 were significantly different between treatment
groups.
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Fig 5. Effect of PG on GnRH-Induced Gonadotropin Subunit Promoter Activities
LβT2 cells were transiently transfected with αGSU-Luc (A), LHβ-Luc (B) and FSHβ-Luc (C)
promoter constructs before being pretreated for 30 min with PGE2 or PGF2α or iloprost (500
nM) followed by addition of GnRH (100 nM for 6 h). Cells were harvested and assayed for an
increase in reporter gene expression expressed as relative light units (RLU), after normalization
of transfection efficiency with an internal control. GnRH significantly increased all three
subunits (P < 0.001, one-way ANOVA). Note that only PGF2α had a significant inhibitory
effect on GnRH induction of LHβ-Luc (*, P < 0.05).
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Fig 6. Expression of Prostanoid Receptors in Rat Pituitaries and Colocalization with LH
Rat pituitary sections were fixed and immunostained with antibodies to EP1 (1:40), EP2, (1:40),
EP3 (1:40), EP4 (1:100), IP (1:100) and FP (1:100) (red). The sections were also stained for
LHβ (green) and nuclear counterstained with TOPRO-3 (blue). Colocalization of prostanoids
receptors and LH is examined by merge on the lower right figure for each receptor (bar, 50
μm). Note that EP1, EP2, IP, and FP colocalize to the gonadotropes.
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Fig 7. Effect of the COX Inhibitor, Indomethacin and PG on GnRH-Induced Gonadotropin
Secretion
Rat pituitaries were pretreated with indomethacin (8 μM), PGE2, PGF2α, or iloprost (500 nM)
for 4 h and further incubated with the drugs with or without GnRH (100 nM) for 3 h
(Indomethacin + GnRH) and 4 h (PG + GnRH). The medium was collected and LH (A and C)
and FSH (B and D) were determined by RIA. Note that indomethacin enhanced GnRH-
stimulated LH, but not FSH release, whereas PGF2α, but not PGE2 or iloprost, inhibited GnRH-
stimulated LH, but not FSH release. One-way ANOVA determined that **, P < 0.01 and *,
P < 0.05 were significantly different between treatment groups.
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Fig 8. Schematic Representation of the Inside-Out Prostanoid Signaling Pathway that Mediates
GnRHR Autoregulation and LH Release
GnRH up-regulates the expression of its receptor (GnRHR) and COX-2 involved in the
synthesis of prostaglandins. This is associated with elevated synthesis and release of various
prostaglandins (PGI2, PGF2α, and PGE2). Prostaglandins (namely PGI2 and PGF2α, but not
PGE2) limit the effect of GnRH on target cells by down-regulating the expression of the
GnRHR. Moreover, elevated PGF2α synthesis (but not PGI2 or PGE2) can have diverging
effects on the GnRH-induced release of gonadotropins from the pituitary, with negative effect
on LH release but no effect on FSH release.
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